Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

206.92 UNCHANGED
Streaming Delayed Price Updated: 5:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
3 Dividend Stocks That Are Screaming Buys in November ↗
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks to Buy Now With $500 ↗
Via The Motley Fool
News headline image
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade ↗
Via The Motley Fool
Topics Stocks
News headline image
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Johnson & Johnson ↗
 
Via Benzinga
News headline image
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
News headline image
This Is What Whales Are Betting On Johnson & Johnson ↗
 
Via Benzinga
News headline image
Industry Comparison: Evaluating Johnson &amp; Johnson Against Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
News headline image
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗
CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
Via Talk Markets
News headline image
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Peering Into Johnson & Johnson's Recent Short Interest ↗
 
Via Benzinga
News headline image
Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs ↗
Johnson & Johnson sues the U.S. government agency over a 340B Drug Pricing Program dispute, arguing the program's misuse. 
Via Benzinga
Topics Lawsuit
News headline image
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever ↗
You'll also like these stocks for their track record of earnings growth. 
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges 
From Inovalon Holdings, Inc.
Via GlobeNewswire
News headline image
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises ↗
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
News headline image
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease ↗
Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks. 
Via Benzinga
News headline image
3 Dividend Growth Stocks You Can Buy and Hold Forever ↗
These healthcare stocks have fantastic dividend track records. 
Via The Motley Fool
News headline image
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas ↗
Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the SPECTREM Phase 3b study, surpassing placebo. 
Via Benzinga
News headline image
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government ↗
In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left. 
Via The Motley Fool
News headline image
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime ↗
These three Vanguard ETFs are worth considering for the long term. 
Via The Motley Fool
Topics ETFs
News headline image
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock ↗
Fewer contenders means fewer constraints on expanding market share. 
Via The Motley Fool
News headline image
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability ↗
The DOJ's U.S. Trustee Program seeks to dismiss Johnson & Johnson's third attempt to settle 60,000 talc lawsuits via bankruptcy, arguing the filing is a bad-faith strategy to avoid liability. 
Via Benzinga
Topics Bankruptcy Lawsuit
News headline image
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises ↗
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
News headline image
What's Going On With Kenvue Stock Monday? ↗
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
Via Benzinga
News headline image
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies ↗
Elf Beauty appeared to rally along with KVUE on Monday. 
Via Investor's Business Daily
Topics Stocks
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.